Novel human myeloid terminal differentiation response gene

Details Novel human myeloid terminal differentiation response gene Novel human myeloid terminal differentiation response gene

C - Chemistry, Metallurgy

12

N

C12N 15/12 (2006.01) A61K 31/70 (2006.01) A61K 31/7088 (2006.01) A61K 38/00 (2006.01) A61K 38/17 (2006.01) A61K 38/19 (2006.01) A61K 48/00 (2006.01) A61P 7/00 (2006.01) A61P 43/00 (2006.01) C07K 14/47 (2006.01) C07K 16/18 (2006.01) C07K 16/24 (2006.01) C12N 5/06 (2006.01) C12N 5/08 (2006.01) C12N 5/10 (2006.01) C12N 15/09 (2006.01) C12N 15/11 (2006.01) C12N 15/19 (2006.01) C12N 15/85 (2006.01) C12P 21/02 (2006.01) C12Q 1/68 (2006.01) G01N 33/15 (2006.01) G01N 33/50 (2006.01) G01N 33/53 (2006.01) G01N 33/574

Patent

CA 2246578

The present invention provides polynucleotide and amino acid sequences which encode and identify a novel human myeloid terminal differentiation response gene designated MYD118. The present invention also provides for MYD118 antisense molecules. The invention further provides genetically engineered expression vectors and host cells for the production of purified MYD118 polypeptide; antibodies, antagonists and inhibitors of MYD118 polypeptide; and pharmaceutical compositions and methods of treatment based on polynucleotide sequences encoding MYD118 polypeptide. The invention specifically provides for use of the MYD118 polynucleotide sequences as a diagnostic composition for the detection of myeloproliferative diseases and leukemias. The invention also relates to therapeutic methods and compositions based upon the nucleotide and amino acid sequences for MYD118. The invention further provides antibodies which specifically bind to MYD118.

La présente invention se rapporte à des séquences de polynucléotides et d'aminoacides qui codent et identifient un nouveau gène de réponse à la différentiation terminale myéloïde d'origine humaine, dénommé MYD118. La présente invention se rapporte également à des molécules anti-sens du myd118. L'invention se rapporte également à des vecteurs et à des cellules hôtes obtenus par génie génétique et destinés à la fabrication de polypeptides de MYD118 purifiés, à des anticorps, des antagonistes et des inhibiteurs du polypeptide de MYD118, ainsi qu'à des compositions pharmaceutiques et à des procédés de traitement utilisant des séquences de polynucléotides codant le polypeptide de MYD118. L'invention concerne particulièrement l'utilisation des séquences de polynucléotides du myd118 en tant que composition d'aide au diagnostic en vue de la détection de maladies myéloprolifératives et de leucémies. L'invention se rapporte en outre à des procédés et à des compositions thérapeutiques dans lesquelles on utilise les séquences de nucléotides et d'aminoacides codant MYD118. Enfin, l'invention se rapporte à des anticorps qui se lient spécifiquement au MYD118.

Affiliated with

Also associated with

Rating

Novel human myeloid terminal differentiation response gene does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Novel human myeloid terminal differentiation response gene, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Novel human myeloid terminal differentiation response gene will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1445800